Marco Meglio, Assistant Managing Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at mmeglio@neurologylive.com
Tracking Therapeutic Progress of Gene-Editing Agent PBGENE-DMD for Duchenne Muscular Dystrophy
May 28th 2025Jeff Smith, PhD, chief executive officer at Precision Biosciences, explained the clinical potential and gene-editing mechanism of PBGENE-DMD, a one-time therapy targeting dystrophin mutations in Duchenne muscular dystrophy.
Investigational Imlifidase Shows Rapid and Sustained Improvement of Guillain-Barré Syndrome Symptoms
May 19th 2025Among patients with severe Guillain-Barré syndrome, imlifidase plus IVIg resulted in improved mobility, strength, and disability scores, with sustained benefit over a 6-month time period.